A groundbreaking advancement in the genetic treatment of deafness has emerged, promising life-changing outcomes for individuals of all ages. Maoli Duan, a consultant at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet in Sweden, emphasized the significance of this development.
Targeting the OTOF Gene
The clinical trial involved ten participants aged between 1 and 24, treated across five hospitals in China. Each individual had a genetic form of deafness caused by mutations in the OTOF gene, which is crucial for the production of otoferlin--a protein necessary for transmitting sound signals from the inner ear to the brain.
Rapid Results After a Single Injection
Researchers utilized a synthetic adeno-associated virus (AAV) to introduce a functional version of the OTOF gene directly into the inner ear via a single injection through the round window of the cochlea. Remarkably, most patients began to experience hearing improvements within just one month. By the six-month mark, all participants demonstrated significant enhancements, with their sound detection levels improving from an average of 106 decibels to 52.
Strongest Gains Seen in Younger Patients
Children, particularly those aged five to eight, exhibited the most substantial improvements. A notable case involved a seven-year-old girl who nearly regained full hearing and was able to engage in conversations with her mother just four months post-treatment. Adults also experienced meaningful advancements in their hearing capabilities.
"Previous smaller studies in China indicated positive outcomes in children, but this is the first instance where the method has been successfully applied to teenagers and adults," Dr. Duan noted. "The improvements in hearing can significantly enhance quality of life, and we will continue to monitor these patients to assess the longevity of these effects."
Treatment Found to Be Safe
The therapy was deemed safe and well-tolerated, with the most common side effect being a decrease in neutrophils, a type of white blood cell. No serious adverse effects were reported during the follow-up period of 6 to 12 months.
Expanding Gene Therapy for Hearing Loss
"OTOF is just the beginning," Dr. Duan stated. "We are expanding our research to include other prevalent genes associated with deafness, such as GJB2 and TMC1. Although these are more challenging to address, preliminary animal studies have shown encouraging results. We are optimistic that individuals with various forms of genetic deafness will eventually have access to effective treatments."
This research was conducted in collaboration with multiple institutions, including Zhongda Hospital at Southeast University in China, and received funding from various Chinese research initiatives, as well as Otovia Therapeutics Inc., the company responsible for developing the gene therapy.
